Tag: DOJ

The impersonator falsely identified plan compliance issues and recommended that sponsors name him as their plan administrator.

Discussion topics include ‘anticompetitive conduct’ by pharmaceutical companies’ ‘regulatory abuse’ and turning insights into action.